Information Provided By:
Fly News Breaks for May 23, 2019
May 23, 2019 | 09:22 EDT
JMP Securities analyst Liisa Bayko maintains an Outperform rating on BioCryst Pharmaceuticals after her talks with two key opinion leader doctors supported her view that HAE patients will want to try an oral option and BCX7353 could be "good enough" for a substantial proportion of them. However, she cut her price target on the shares to $10 from $18 to account for the fact that she lowered her U.S. launch price estimate to $250,000 from $500,000 annually.
News For BCRX From the Last 2 Days
There are no results for your query BCRX